Sara D. Lundsten
Uppsala, C 75185, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Journal: Cancer research
Published: September 05, 2025
Predicting Care Times at PACU.
Journal: Studies in health technology and informatics
Published: May 17, 2025
Using AI to Predict Patients' Length of Stay: PACU Staff's Needs and Expectations for Developing and Implementing an AI System.
Journal: Journal of nursing management
Published: June 03, 2024
Photoactive immunoconjugates for targeted photodynamic therapy of cancer.
Journal: Journal of photochemistry and photobiology. B, Biology
Published: December 08, 2022
p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids.
Journal: Biomolecules
Published: September 29, 2021
Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks.
Journal: Nanomaterials (Basel, Switzerland)
Published: March 20, 2020
The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
Journal: Scientific reports
Published: October 04, 2019
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts.
Journal: European journal of nuclear medicine and molecular imaging
Published: August 08, 2019
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
Journal: Cell reports
Published: June 30, 2019
The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
Journal: International journal of oncology
Published: March 08, 2019
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Journal: Cancer research
Published: February 09, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026